Association between specific mutations in KRAS codon 12 and colorectal liver metastasis

Georgios Antonios Margonis, Yuhree Kim, Gaya Spolverato, Aslam Ejaz, Rohan Gupta, David Cosgrove, Robert Anders, Georgios Karagkounis, Michael A. Choti, Timothy M. Pawlik

Research output: Contribution to journalArticlepeer-review

102 Scopus citations


IMPORTANCE Currently, one of the most commonly available biomarkers in the treatment of patients with colorectal liver metastases (CRLM) is the Kirsten rat sarcoma viral oncogene homolog (KRAS); however, the prognostic implications of specific mutations of the KRAS gene are still not well defined. OBJECTIVE To investigate the prognostic impact of specific KRAS mutations on patients undergoing liver resection for CRLM. DESIGN, SETTING, AND PARTICIPANTS This retrospective single-center studywas conducted from January 1, 2003, to December 31, 2013. Data about specific KRAS mutations for 331 patients who underwent hepatic resection for CRLM at Johns Hopkins Hospital between 2003 and 2013 were analyzed. Clinicopathological characteristics, perioperative details, and outcomes were stratified by specific KRAS mutation at codons 12 and 13. INTERVENTION Resection of CRLM. MAIN OUTCOMES AND MEASURES Overall survival (OS) and recurrence-free survival. RESULTS A mutated KRAS (mtKRAS) was identified in 91 patients (27.5%). At a median follow-up of 27.4 months, recurrence was observed in 48 patients (52.7%) with mtKRAS and 130 patients (54.2%) with wild-type KRAS (wtKRAS) (P =.82). Median and 5-year survival among patients with mtKRAS was 32.4 months and 32.7%, respectively, vs 58.5 months and 46.9%, respectively, for patients with wtKRAS (P =.02). Patients with KRAS codon 12 mutations had worse OS (hazard ratio [HR], 1.54; 95%CI, 1.05-2.27; P =.03) vs those with wtKRAS, whereas a KRAS codon 13 mutation was not associated with prognosis (HR, 1.47; 95%CI, 0.83-2.62; P =.19). Among the 6 most common mutations in codons 12 and 13, only G12V (HR, 1.78; 95%CI, 1.00-3.17; P =.05) and G12S (HR, 3.33; 95%CI, 1.22-9.10; P =.02) were associated with worse OS compared with patients with wtKRAS (both P <.05). Among patients who recurred, G12V (HR, 2.96; 95%CI, 1.32-6.61; P =.01), G12C (HR, 6.74; 95%CI, 2.05-22.2; P =.002), and G12S mutations (HR, 4.91; 95%CI, 1.52-15.8; P =.01) were associated with worse OS (both P <.05).

Original languageEnglish (US)
Pages (from-to)722-729
Number of pages8
JournalJAMA Surgery
Issue number8
StatePublished - Aug 1 2015

ASJC Scopus subject areas

  • Surgery


Dive into the research topics of 'Association between specific mutations in KRAS codon 12 and colorectal liver metastasis'. Together they form a unique fingerprint.

Cite this